September 8, 2023 01:42 PM EDT
Pharma
FDA+

Citius Phar­ma­ceu­ti­cals looks to re­file for­mer Ei­sai can­cer drug in ear­ly 2024

Nicole DeFeudis

Editor

Citius Phar­ma­ceu­ti­cals plans to re­file its ex­per­i­men­tal drug for a rare blood can­cer in ear­ly 2024 fol­low­ing an FDA re­jec­tion in Ju­ly.

The drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

Sion­na and Odyssey end JPM week with IPO fil­ings

An­oth­er US biotech emerges with drug can­di­date from Chi­na-based Keymed

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times